基于EB病毒检测鼻咽癌的筛查性能与操作可行性:两种替代方法的直接比较
研究在台湾地区819例鼻咽癌病例与1768例对照中直接比较EBV抗体评分与血浆EBV DNA算法的筛查性能。EBV DNA算法灵敏度93.2%、特异度98.1%,均显著高于抗体评分的88.4%和94.9%;早期病例两者灵敏度相近。作者认为需开展成本效果研究指导筛查实施。
要点
- EBV DNA算法灵敏度93.2%、特异度98.1%,显著优于EBV抗体评分。
- 早期鼻咽癌灵敏度:抗体评分87.1% vs DNA算法87.0%,无显著差异。
- 在高发病区,两种方法需筛查人数相近,但DNA算法阳性预测值更高。
核心结论
- EBV抗体评分与血浆EBV DNA对鼻咽癌检测均显示高灵敏度和特异度,其中EBV抗体评分性能略低。
- 作者指出需开展成本效果研究以指导筛查实施。
研究设计与样本
- 研究纳入2010年至2014年诊断的819例台湾地区鼻咽癌病例(其中213例为美国癌症联合委员会第7版I和II期早期病例)和1768例来自同一地区的对照,按年龄和性别与病例进行频数匹配。
主要发现
- EBV抗体评分对鼻咽癌的灵敏度为88.4%(95% CI,86.1至90.6),特异度为94.9%(95% CI,93.8至96.0)。
- EBV DNA算法的灵敏度显著更高,为93.2%(95% CI,91.3至94.9;P=1.33×10^-4),特异度也显著更高,为98.1%(95% CI,97.3至98.8;P=3.53×10^-7)。
- 对于早期鼻咽癌,EBV抗体评分的灵敏度为87.1%(95% CI,82.7至92.4),EBV DNA算法为87.0%(95% CI,81.9至91.5),两者比较P=0.514。
- 在鼻咽癌发病率为20-100/10万人年的地区(如中国南方和香港居民),两种方法的需筛查人数相近:EBV抗体评分为5656至1131,EBV DNA算法为5365至1073。
- 在上述地区,EBV抗体评分的阳性预测值范围为0.4%至1.7%,EBV DNA算法为1.0%至4.7%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Two Epstein-Barr virus (EBV)-based testing approaches have shown promise for early detection of nasopharyngeal carcinoma (NPC). Neither has been independently validated nor their performance compared. We compared their diagnostic performance in an independent population. METHODS: We tested blood samples from 819 incident Taiwanese NPC cases (213 early-stage, American Joint Committee on Cancer version 7 stages I and II) diagnosed from 2010 to 2014 and from 1,768 controls from the same region, frequency matched to cases on age and sex. We compared an EBV antibody score using immunoglobulin A antibodies measured by enzyme-linked immunosorbent assay (EBV antibody score) and plasma EBV DNA load measured by real-time PCR followed by next-generation sequencing (NGS) among EBV DNA-positive individuals (EBV DNA algorithm). RESULTS: EBV antibodies and DNA load were measured for 2,522 (802 cases; 1,720 controls) and 2,542 (797 cases; 1,745 controls) individuals, respectively. Of the 898 individuals positive for plasma EBV DNA and therefore eligible for NGS, we selected 442 (49%) for NGS testing. The EBV antibody score had a sensitivity of 88.4% (95% CI, 86.1 to 90.6) and a specificity of 94.9% (95% CI, 93.8 to 96.0) for NPC. The EBV DNA algorithm yielded significantly higher sensitivity (93.2%; 95% CI, 91.3 to 94.9; P = 1.33 × 10-4) and specificity (98.1%; 95% CI, 97.3 to 98.8; P = 3.53 × 10-7). For early-stage NPC, the sensitivities were 87.1% (95% CI, 82.7 to 92.4) for the EBV antibody score and 87.0% (95% CI, 81.9 to 91.5) for the EBV DNA algorithm (P = .514). For regions with a NPC incidence of 20-100/100,000 person-years (eg, residents in southern China and Hong Kong), these two approaches yielded similar numbers needed to screen (EBV antibody score: 5,656-1,131; EBV DNA algorithm: 5,365-1,073); positive predictive values ranged from 0.4% to 1.7% and 1.0% to 4.7%, respectively. CONCLUSION: We demonstrated high sensitivity and specificity of EBV antibody and plasma EBV DNA for NPC detection, with slightly inferior performance of the EBV antibody score. Cost-effectiveness studies are needed to guide screening implementation.
引用
- Lou PJ, Jacky Lam WK, Hsu WL, et al. Performance and Operational Feasibility of Epstein-Barr Virus-Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches. J Clin Oncol. 2023. PMID: 37478397. doi:10.1200/JCO.22.01979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。